ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

193
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
06 Nov 2024 08:55

Sino Biopharm (1177.HK) To Acquire Hob Biotech (688656.CH)- Time to Buy Hob and Sell Sino Biopharm?

The price Sino Biopharm pays to acquire Hob is expensive.The main purpose is not asset appreciation but achieve A-share listing. Hob's future...

Logo
398 Views
Share
02 Oct 2024 22:40

Quiddity Leaderboard HSCEI Dec 24: Two Changes Likely; US$474mn Capping Flows One-Way

The one-way flow estimate for US$474mn translates to a turnover of roughly 4.2%. The final capping flows will be decided on 3rd December 2024.

Share
19 Aug 2024 08:55

Sino Biopharmaceutical (1177.HK) 24H1 - The Concerns Behind the Performance Turnaround

​Sino Biopharma sees turnaround in 24H1 but faces uncertainty in achieving revenue target of HK$100 billion by 2030 due to lack of competitiveness...

Logo
248 Views
Share
07 Apr 2024 14:06

China Healthcare Weekly (Apr.6) - Boom of TCM Injections Is Coming, Defects in GLP-1s, Sino Biopharm

Payment policy relaxation will drive rapid sales growth of TCM injection.GLP-1 has defects-patients will lose not only fat but also muscle. Mr...

Logo
413 Views
Share
18 Oct 2024 23:12

China Traditional Chinese Medicine (570 HK): Disaster as Offer Lapses, Potential Deal Break Price

This deal break caught many, including me, off guard. There are lessons to be learnt and questions to be asked. Shareholders will have a bruising...

Logo
1.1k Views
Share
x